We chat with Anna Marie Wagner, the SVP of corporate development at Gingko Bioworks, a synthetic biology company that recently came public and is part of Invest Vegan’s flagship strategy. We chat about how Gingko evolved its funding sources over time, the firm’s decision to pursue a horizontal/service provider business model, and how she’ll judge the success of her company and the broader synthetic biology industry going forward.